This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cowan, K. H. Articles by Nienhuis, A. Search for Related Content PubMed PubMed Citation Articles by Cowan, K. H. Articles by Nienhuis, A.

Paclitaxel Chemotherapy after Autologous Stem-Cell Transplantation and Engraftment of Hematopoietic Cells Transduced with a Retrovirus Containing the Multidrug Resistance Complementary DNA (MDR1) in Metastatic Breast Cancer Patients

National Cancer Institute [K. H. C., J. A. M., H. H., J. A. Z., J. O., E. S., G. C., M. N., S. S., W. W., A. A., M. M. G., I. P.], National Heart Lung and Blood Institute [C. D., K. M.], and Clinical Center [K. H., C. Ca., B. G., E. J. R., S. F. L., C. Ch.], National Institutes of Health, Bethesda, Maryland 20892; St. Jude Children’s Research Hospital. Memphis, Tennessee 38105 [B. S., A. N.]; and Genetic Therapy Inc., Gaithersburg, Maryland 20878 [Y. C., Y. N. C.]

The MDR1 multidrug resistance gene confers resistance to natural-product anticancer drugs including paclitaxel. We conducted a clinical gene therapy study to determine whether retroviral-mediated transfer of MDR1 in human hematopoietic cells would result in stable engraftment, and possibly expansion, of cells containing this gene after treatment with myelosuppressive doses of paclitaxel. Patients with metastatic breast cancer who achieved a complete or partial remission after standard chemotherapy were eligible for the study. Hematopoietic stem cells (HSCs) were collected by both peripheral blood apheresis and bone marrow harvest after mobilization with a single dose of cyclophosphamide (4 g/m²) and daily filgrastim therapy (10 µg/kg/day). After enrichment for CD34+ cells, one-third of each collection was incubated ex vivo for 72 h with a replication-incompetent retrovirus containing the MDR1 gene (G1MD) in the presence of stem-cell factor, interleukin 3, and interleukin 6. The remaining CD34+ cells were stored without further manipulation. All of the CD34+ cells were reinfused for hematopoietic rescue after conditioning chemotherapy with ifosfamide, carboplatin, and etoposide regimen. After hematopoietic recovery, patients received six cycles of paclitaxel (175 mg/m² every 3 weeks). Bone marrow and serial peripheral blood samples were obtained and tested for the presence of the MDR1 transgene using a PCR assay. Six patients were enrolled in the study and four patients received infusion of genetically altered cells. The ex vivo transduction efficiency, estimated by the PCR assay, ranged from 0.1 to 0.5%. Three of the four patients demonstrated engraftment of cells containing the MDR1 transgene. The estimated percentage of granulocytes containing the MDR1 transgene ranged from a maximum of 9% of circulating nucleated cells down to the limit of detection of 0.01%. One patient remained positive for the MDR1 transgene throughout all six cycles of paclitaxel therapy, whereas the other 2 patients showed a decrease in the number of cells containing the transgene to undetectable levels. Despite the low level of engraftment of MDR1-marked cells, a correlation was observed between the relative number of granulocytes containing the MDR1 transgene and the granulocyte nadir after paclitaxel therapy. No adverse reactions to the genetic manipulation procedures were detected. Therefore, engraftment of human HSCs transduced with the MDR1 gene can be achieved. However, the overall transduction efficiency and stable engraftment of gene-modified HSCs must be improved before MDR1 gene therapy and in vivo selection with anticancer drugs can be reliably used to protect cancer patients from drug-related myelosuppression.

This article has been cited by other articles:

				F. Bozorgmehr, S. Laufs, S. E. Sellers, I. Roeder, W. J. Zeller, C. E. Dunbar, and S. Fruehauf No Evidence of Clonal Dominance in Primates up to 4 Years Following Transplantation of Multidrug Resistance 1 Retrovirally Transduced Long-Term Repopulating Cells Stem Cells, October 1, 2007; 25(10): 2610 - 2618. [Abstract] [Full Text] [PDF]

				C. R. Ball, I. H. Pilz, M. Schmidt, S. Fessler, D. A. Williams, C. von Kalle, and H. Glimm Stable differentiation and clonality of murine long-term hematopoiesis after extended reduced-intensity selection for MGMT P140K transgene expression Blood, September 15, 2007; 110(6): 1779 - 1787. [Abstract] [Full Text] [PDF]

				A. Al-Hendy and S. Salama Gene therapy and uterine leiomyoma: a review Hum. Reprod. Update, July 1, 2006; 12(4): 385 - 400. [Abstract] [Full Text] [PDF]

				T. Neff, B. C. Beard, and H.-P. Kiem Survival of the fittest: in vivo selection and stem cell gene therapy Blood, March 1, 2006; 107(5): 1751 - 1760. [Abstract] [Full Text] [PDF]

				W. Wagner, S. Laufs, J. Blake, C. Schwager, X. Wu, J. W. Zeller, A. D. Ho, and S. Fruehauf Retroviral Integration Sites Correlate with Expressed Genes in Hematopoietic Stem Cells Stem Cells, September 1, 2005; 23(8): 1050 - 1058. [Abstract] [Full Text] [PDF]

				M. L. Lucas, N. E. Seidel, C. D. Porada, J. G. Quigley, S. M. Anderson, H. L. Malech, J. L. Abkowitz, E. D. Zanjani, and D. M. Bodine Improved transduction of human sheep repopulating cells by retrovirus vectors pseudotyped with feline leukemia virus type C or RD114 envelopes Blood, July 1, 2005; 106(1): 51 - 58. [Abstract] [Full Text] [PDF]

				H. Zhu, W. Guo, L. Zhang, J. J. Davis, F. Teraishi, S. Wu, X. Cao, J. Daniel, W. R. Smythe, and B. Fang Bcl-XL small interfering RNA suppresses the proliferation of 5-fluorouracil-resistant human colon cancer cells Mol. Cancer Ther., March 1, 2005; 4(3): 451 - 456. [Abstract] [Full Text] [PDF]

				T. Neff, B. C. Beard, L. J. Peterson, P. Anandakumar, J. Thompson, and H.-P. Kiem Polyclonal chemoprotection against temozolomide in a large-animal model of drug resistance gene therapy Blood, February 1, 2005; 105(3): 997 - 1002. [Abstract] [Full Text] [PDF]

				L. Barzon, M. Boscaro, and G. Palu Endocrine Aspects of Cancer Gene Therapy Endocr. Rev., February 1, 2004; 25(1): 1 - 44. [Abstract] [Full Text] [PDF]

				D. A. Persons, J. A. Allay, A. Bonifacino, T. Lu, B. Agricola, M. E. Metzger, R. E. Donahue, C. E. Dunbar, and B. P. Sorrentino Transient in vivo selection of transduced peripheral blood cells using antifolate drug selection in rhesus macaques that received transplants with hematopoietic stem cells expressing dihydrofolate reductase vectors Blood, February 1, 2004; 103(3): 796 - 803. [Abstract] [Full Text] [PDF]

				D. A. Persons, E. R. Allay, N. Sawai, P. W. Hargrove, T. P. Brent, H. Hanawa, A. W. Nienhuis, and B. P. Sorrentino Successful treatment of murine {beta}-thalassemia using in vivo selection of genetically modified, drug-resistant hematopoietic stem cells Blood, July 15, 2003; 102(2): 506 - 513. [Abstract] [Full Text] [PDF]

				S L Preston, M R Alison, S J Forbes, N C Direkze, R Poulsom, and N A Wright The new stem cell biology: something for everyone Mol. Pathol., April 1, 2003; 56(2): 86 - 96. [Abstract] [Full Text] [PDF]

				C. L. Sweeney, J. L. Frandsen, C. M. Verfaillie, and R. S. McIvor Trimetrexate Inhibits Progression of the Murine 32Dp210 Model of Chronic Myeloid Leukemia in Animals Expressing Drug-resistant Dihydrofolate Reductase Cancer Res., March 15, 2003; 63(6): 1304 - 1310. [Abstract] [Full Text] [PDF]

				C. Baum, J. Dullmann, Z. Li, B. Fehse, J. Meyer, D. A. Williams, and C. von Kalle Side effects of retroviral gene transfer into hematopoietic stem cells Blood, March 15, 2003; 101(6): 2099 - 2113. [Abstract] [Full Text] [PDF]

				T. Neff, P. A. Horn, V. E. Valli, A. M. Gown, S. Wardwell, B. L. Wood, C. von Kalle, M. Schmidt, L. J. Peterson, J. C. Morris, et al. Pharmacologically regulated in vivo selection in a large animal Blood, August 28, 2002; 100(6): 2026 - 2031. [Abstract] [Full Text] [PDF]

				T. Licht, M. Haskins, P. Henthorn, S. E. Kleiman, D. M. Bodine, T. Whitwam, J. M. Puck, M. M. Gottesman, and J. R. Melniczek Drug selection with paclitaxel restores expression of linked IL-2 receptor gamma -chain and multidrug resistance (MDR1) transgenes in canine bone marrow PNAS, February 20, 2002; (2002) 52712199. [Abstract] [Full Text] [PDF]

				S. E. Sellers, J. F. Tisdale, B. A. Agricola, M. E. Metzger, R. E. Donahue, C. E. Dunbar, and B. P. Sorrentino The effect of multidrug-resistance 1 gene versus neo transduction on ex vivo and in vivo expansion of rhesus macaque hematopoietic repopulating cells Blood, March 15, 2001; 97(6): 1888 - 1891. [Abstract] [Full Text] [PDF]

				P. A Fontes and A. W Thomson Stem cell technology BMJ, November 13, 1999; 319(7220): 1308 - 1308. [Full Text]

				A. B. Deisseroth Clinical Trials Involving Multidrug Resistance Transcription Units in Retroviral Vectors Clin. Cancer Res., July 1, 1999; 5(7): 1607 - 1609. [Full Text] [PDF]

				T. Licht, M. Haskins, P. Henthorn, S. E. Kleiman, D. M. Bodine, T. Whitwam, J. M. Puck, M. M. Gottesman, and J. R. Melniczek Drug selection with paclitaxel restores expression of linked IL-2 receptor gamma -chain and multidrug resistance (MDR1) transgenes in canine bone marrow PNAS, March 5, 2002; 99(5): 3123 - 3128. [Abstract] [Full Text] [PDF]